Fevipiprant in the treatment of asthma

References

• Global Initative for Asthma. Global Strategy for Asthma Management and Prevention; 2017.
   Google Scholar
• Peters SP, Ferguson G, Deniz Y, et al. Uncontrolled asthma: a review of the prevalence, disease burden and options for treatment. Respir Med. 2006 Jul;100:1139–1151.
   PubMed Web of Science ®Google Scholar
• Royal College of Physicians. Why asthma still kills: the National Review of Asthma Deaths (NRAD) Confidential Enquiry Report.
   Google Scholar
• Haldar P, Pavord ID, Shaw DE, et al. Cluster analysis and clinical asthma phenotypes. Am J Respir Crit Care Med. 2008 Aug 01;178:218–224.
   PubMed Web of Science ®Google Scholar
• Moore WC, Hastie AT, Li X, et al. Sputum neutrophils are associated with more severe asthma phenotypes using cluster analysis. J Allergy Clin Immunol. 2014 Dec 09;133:1557.e5-1563.e5.
   Web of Science ®Google Scholar
• Green RH, Brightling CE, McKenna S, et al. Asthma exacerbations and sputum eosinophil counts: a randomised controlled trial. The Lancet. 2002;360:1715–1721.
   PubMed Web of Science ®Google Scholar
• Wenzel S. Severe asthma: from characteristics to phenotypes to endotypes. Clin Exp Allergy. 2012 May;42:650–658.
   PubMed Web of Science ®Google Scholar
• Lambrecht BN, Hammad H. The immunology of asthma. Nat Immunol. 2015 Jan;16:45–56.
   PubMed Web of Science ®Google Scholar
• Israel E, Reddel HK. Severe and difficult-to-treat asthma in adults. N Engl J Med. 2017 Sep 07;377:965–976.
   PubMed Web of Science ®Google Scholar
• Russell RJ, Brightling C. Pathogenesis of asthma: implications for precision medicine. Clin Sci (Lond). 2017 Jul 15;131:1723–1735.
   PubMed Web of Science ®Google Scholar
• Nagata K, Hirai H. The second PGD(2) receptor CRTH2: structure, properties, and functions in leukocytes. Prostaglandins Leukot Essent Fatty Acids. 2003 Aug-Sep;69:169–177.
   PubMed Web of Science ®Google Scholar
• Hirai H, Tanaka K, Yoshie O, et al. Prostaglandin D2 selectively induces chemotaxis in T helper type 2 cells, eosinophils, and basophils via seven-transmembrane receptor CRTH2. J Exp Med. 2001 Jan 15;193:255–261.
   PubMed Web of Science ®Google Scholar
• Fredriksson R, Lagerstrom MC, Lundin LG, et al. The G-protein-coupled receptors in the human genome form five main families. Phylogenetic analysis, paralogon groups, and fingerprints. Mol Pharmacol. 2003 Jun;63:1256–1272.
   PubMed Web of Science ®Google Scholar
• Sawyer N, Cauchon E, Chateauneuf A, et al. Molecular pharmacology of the human prostaglandin D2 receptor, CRTH2. Br J Pharmacol. 2002;137:1163–1172.
   PubMed Web of Science ®Google Scholar
• Cosmi L, Annunziato F, Galli MIG, et al. CRTH2 is the most reliable marker for the detection of circulating human type 2 Th and type 2 T cytotoxic cells in health and disease. Eur J Immunol. 2000;30:2972–2979.
   PubMed Web of Science ®Google Scholar
• Xue L, Salimi M, Panse I, et al. Prostaglandin D2 activates group 2 innate lymphoid cells through chemoattractant receptor-homologous molecule expressed on TH2 cells. J Allergy Clin Immunol. 2014;133:1184–1194.
   PubMed Web of Science ®Google Scholar
• Moon TC, Campos-Alberto E, Yoshimura T, et al. Expression of DP2 (CRTh2), a prostaglandin D(2) receptor, in human mast cells. PLoS One. 2014;9:e108595.
   PubMed Web of Science ®Google Scholar
• Wong KL, Tai JJ, Wong WC, et al. Gene expression profiling reveals the defining features of the classical, intermediate, and nonclassical human monocyte subsets. Blood. 2011 Aug;04(118):e16–e31.
   Google Scholar
• Frankenberger M, Hofer TP, Marei A, et al. Transcript profiling of CD16-positive monocytes reveals a unique molecular fingerprint. Eur J Immunol. 2012;42:957–974.
   PubMed Web of Science ®Google Scholar
• Ancuta P, Liu KY, Misra V, et al. Transcriptional profiling reveals developmental relationship and distinct biological functions of CD16+ and CD16- monocyte subsets. BMC Genomics. 2009 Aug 27;10:403.
   PubMed Web of Science ®Google Scholar
• James A, Carroll N. Airway smooth muscle in health and disease; methods of measurement and relation to function. Eur Respir J. 2000 Apr;15:782–789.
   PubMed Web of Science ®Google Scholar
• Bergeron C, Tulic MK, Hamid Q. Airway remodelling in asthma: from benchside to clinical practice. Can Respir J. 2010 Jul-Aug;17:E85–E93.
   PubMed Web of Science ®Google Scholar
• Huber HL, Koessler KK. The pathology of bronchial asthma. Arch Intern Med. 1922;30:689–760.
   Google Scholar
• Berair R, Hartley R, Mistry V, et al. Associations in asthma between quantitative computed tomography and bronchial biopsy-derived airway remodelling. Eur Respir J. 2017 May;49:1601507.
   PubMed Web of Science ®Google Scholar
• Chung KF, Wenzel SE Brozek JL, et al. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J. 2014;43:343–373.
   PubMed Web of Science ®Google Scholar
• Makela MJ, Backer V, Hedegaard M, et al. Adherence to inhaled therapies, health outcomes and costs in patients with asthma and COPD. Respir Med. 2013 Oct;107:1481–1490.
   PubMed Web of Science ®Google Scholar
• Espiritu J. Factors associated with poor asthma control in the Behavioral Risk Factor Surveillance System (BRFSS) asthma call-back survey 2009. Chest. 2013 Oct;2013:72A–72A.
   Google Scholar
• Hanania NA, Chapman KR, Kesten S. Adverse effects of inhaled corticosteroids. Am J Med. 1995 Feb;98:196–208.
   PubMed Web of Science ®Google Scholar
• Sweeney J, Patterson CC, Menzies-Gow A, et al. Comorbidity in severe asthma requiring systemic corticosteroid therapy: cross-sectional data from the optimum patient care research database and the British thoracic difficult asthma registry. Thorax. 2016;71:339–346.
   PubMed Web of Science ®Google Scholar
• Anderson DE, Kew KM, Boyter AC. Long-acting muscarinic antagonists (LAMA) added to inhaled corticosteroids (ICS) versus the same dose of ICS alone for adults with asthma. Cochrane Database Syst Rev. 2015 Aug 24;8:CD011397.
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Care Excellence. Omalizumab for treating severe persistent allergic asthma; 2013 [cited 2017 Nov 21]. Available from https://www.nice.org.uk/guidance/ta278
   Google Scholar
• National Institute for Health and Care and Excellence. Mepolizumab for treating severe refractory eosinophilic asthma. 2017 [cited 2017 Nov 21]. Available from https://www.nice.org.uk/guidance/ta431
   Google Scholar
• National Institute for Health and Care Excellence. Reslizumab for treating severe eosinophilic asthma; 2017. [cited 2017 Nov 21]. Available from https://www.nice.org.uk/guidance/ta479
   Google Scholar
• Normansell R, Walker S, Milan SJ, et al. Omalizumab for asthma in adults and children. Cochrane Database Syst Rev. 2014 Jan 13;1:CD003559.
   PubMedGoogle Scholar
• Haldar P, Brightling CE, Hargadon B, et al. Mepolizumab and exacerbations of refractory eosinophilic asthma. N Engl J Med. 2009 Mar 05;360:973–984.
   PubMed Web of Science ®Google Scholar
• Pavord ID, Korn S, Howarth P, et al. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. Lancet. 2012 Aug 18;380:651–659.
   PubMed Web of Science ®Google Scholar
• Ortega HG, Liu MC, Pavord ID, et al. Mepolizumab treatment in patients with severe eosinophilic asthma. N Engl J Med. 2014 Sep 25;371:1198–1207.
   PubMed Web of Science ®Google Scholar
• Bel EH, Wenzel SE, Thompson PJ, et al. Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma. N Engl J Med. 2014 Sep 25;371:1189–1197.
   PubMed Web of Science ®Google Scholar
• Castro M, Zangrilli J, Wechsler ME, et al. Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials. Lancet Resp Med. 2015;3:355–366.
   PubMed Web of Science ®Google Scholar
• Castro M, Rubin AS, Laviolette M, et al. Effectiveness and safety of bronchial thermoplasty in the treatment of severe asthma: a multicenter, randomized, double-blind, sham-controlled clinical trial. Am J Respir Crit Care Med. 2010 Jan 15;181:116–124.
   PubMed Web of Science ®Google Scholar
• Castro M, Wenzel SE, Bleecker ER, et al. Benralizumab, an anti-interleukin 5 receptor alpha monoclonal antibody, versus placebo for uncontrolled eosinophilic asthma: a phase 2b randomised dose-ranging study. Lancet Resp Med. 2014;2:879–890.
   PubMed Web of Science ®Google Scholar
• FitzGerald JM, Bleecker ER, Nair P, et al. Benralizumab, an anti-interleukin-5 receptor alpha monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2016 Oct 29;388:2128–2141.
   PubMed Web of Science ®Google Scholar
• Bleecker ER, FitzGerald JM, Chanez P, et al. Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting beta2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial. Lancet. 2016 Oct 29;388:2115–2127.
   PubMed Web of Science ®Google Scholar
• Nair P, Wenzel S, Rabe KF, et al. Oral glucocorticoid-sparing effect of benralizumab in severe asthma. N Engl J Med. 2017 Jun 22;376:2448–2458.
   PubMed Web of Science ®Google Scholar
• Wenzel S, Castro M, Corren J, et al. Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting beta2 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial. Lancet. 2016 Jul 02;388:31–44.
   PubMed Web of Science ®Google Scholar
• Corren J, Parnes JR, Wang L, et al. Tezepelumab in adults with uncontrolled asthma. N Engl J Med. 2017 Sep 07;377:936–946.
   PubMed Web of Science ®Google Scholar
• Gibson PG, Yang IA, Upham JW, et al. Effect of azithromycin on asthma exacerbations and quality of life in adults with persistent uncontrolled asthma (AMAZES): a randomised, double-blind, placebo-controlled trial. Lancet. 2017 Aug 12;390(10095):659–668.
   PubMed Web of Science ®Google Scholar
• Fajt ML, Wenzel SE. Asthma phenotypes and the use of biologic medications in asthma and allergic disease: the next steps toward personalized care. J Allergy Clin Immunol. 2015 Feb;135:299–310.
   PubMed Web of Science ®Google Scholar
• Cahill KN, Katz HR, Cui J, et al. KIT inhibition by imatinib in patients with severe refractory asthma. New England J Med. 2017;376:1911–1920.
   PubMed Web of Science ®Google Scholar
• Erpenbeck VJ, Vets E, Gheyle L, et al. Pharmacokinetics, safety, and tolerability of fevipiprant (QAW039), a novel CRTh2 receptor antagonist: results from 2 randomized, phase 1, placebo-controlled studies in healthy volunteers. Clin Pharm Drug Dev. 2016 Jul;5:306–313.
   PubMed Web of Science ®Google Scholar
• Gonem S, Berair R, Singapuri A, et al. Fevipiprant, a prostaglandin D2 receptor 2 antagonist, in patients with persistent eosinophilic asthma: a single-centre, randomised, double-blind, parallel-group, placebo-controlled trial. Lancet Resp Med. 2016 Sep;4:699–707.
   PubMed Web of Science ®Google Scholar
• Saunders RM, Kaul H, Berair R, et al. Fevipiprant reduces airway smooth muscle mass in asthma via antagonism of the prostaglandin D2 receptor 2 (DP2). Am J Respir Crit Care Med Scientific Conf Proceedings. 2017 May.
   Google Scholar
• Erpenbeck VJ, Popov TA, Miller D, et al. The oral CRTh2 antagonist QAW039 (fevipiprant): a phase II study in uncontrolled allergic asthma. Pulm Pharmacol Ther. 2016 Aug;39:54–63.
   PubMed Web of Science ®Google Scholar
• Bateman ED, Guerreros AG, Brockhaus F, et al. Fevipiprant, an oral prostaglandin DP2 receptor (CRTh2) antagonist, in allergic asthma uncontrolled on low-dose inhaled corticosteroids. Eur Respir J. 2017 Aug;50:1700670.
   PubMed Web of Science ®Google Scholar
• NCT02555683. A 52-week, multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of QAW039 when added to existing asthma therapy in patients with uncontrolled severe asthma. LUSTER 1 [cited 2017 Nov 21]. Available from https://www.clinicaltrials.gov/ct2/show/NCT02555683
   Google Scholar
• NCT02563067. A 52-week, multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of QAW039 when added to existing asthma therapy in patients with uncontrolled severe asthma. LUSTER 2 [cited 2017 Nov 21]. Available from https://www.clinicaltrials.gov/ct2/show/NCT02563067
   Google Scholar
• Barnes N, Pavord I, Chuchalin A, et al. A randomized, double-blind, placebo-controlled study of the CRTH2 antagonist OC000459 in moderate persistent asthma. Clin Exp Allergy. 2012;42:38–48.
   PubMed Web of Science ®Google Scholar
• Singh D, Cadden P, Hunter M, et al. Inhibition of the asthmatic allergen challenge response by the CRTH2 antagonist OC000459. Eur Respir J. 2013;41:46–52.
   PubMed Web of Science ®Google Scholar
• Pettipher R, Hunter MG, Perkins CM, et al. Heightened response of eosinophilic asthmatic patients to the CRTH2 antagonist OC000459. Allergy. 2014;69:1223–1232.
   PubMed Web of Science ®Google Scholar
• Miller D, Wood C, Bateman E, et al. A randomized study of BI 671800, a CRTH2 antagonist, as add-on therapy in poorly controlled asthma. Allergy Asthma Proc. 2017 Mar 01;38:157–164.
   PubMed Web of Science ®Google Scholar
• Hall IP, Fowler AV, Gupta A, et al. Efficacy of BI 671800, an oral CRTH2 antagonist, in poorly controlled asthma as sole controller and in the presence of inhaled corticosteroid treatment. Pulm Pharmacol Ther. 2015;32:37–44.
   PubMed Web of Science ®Google Scholar
• Wenzel SE, Hopkins R, Saunders M, et al. Safety and efficacy of ARRY-502, a potent, selective, oral CRTh2 antagonist, in patients with mild to moderate Th2-driven asthma. J Allergy Clin Immunol. 2014;133:Ab4–Ab4.
   Web of Science ®Google Scholar
• Busse W, Wenzel SE, Meltzer EO, et al. Safety and efficacy of the prostaglandin D2 receptor antagonist AMG 853 in asthmatic patients. J Allergy Clin Immunol. 2013 Feb;131(2):339–345.
   PubMed Web of Science ®Google Scholar
• Diamant Z, Sidharta PN, Singh D, et al. Setipiprant, a selective CRTH2 antagonist, reduces allergen-induced airway responses in allergic asthmatics. Clin Exp Allergy. 2014;44:1044–1052.
   PubMed Web of Science ®Google Scholar
• NCT01225315. A study of ACT-129968 in adult patients with partly controlled asthma. (CONTROL) [cited 2017 Nov 21]. Available from https://www.clinicaltrials.gov/ct2/show/NCT01225315
   Google Scholar
• NCT00758589. A double-blind, randomised, parallel group, multicentre phase IIb, placebo-controlled, 1 month dose response study of AZD1981 in asthma patients uncontrolled on inhaled steroids. [cited 2017 Nov 21]. Available from https://www.clinicaltrials.gov/ct2/show/NCT00758589
   Google Scholar
• NCT01197794. Investigation of efficacy, safety and tolerability of once and twice daily doses of AZD1981 in asthmatic patients. [cited 2017 Nov 21]. Available from https://www.clinicaltrials.gov/ct2/show/NCT01197794
   Google Scholar